Metastatic pancreatic cancer: Emerging strategies in chemotherapy and palliative care

Oncologist

Volumn 8, Issue 1, 2003, Pages 18-34

  El Kamar, Francois G ^a   Grossbard, Michael L ^a   Kozuch, Peter S ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Chemotherapy; Pain control; Palliative care; Pancreatic cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; CANNABINOID; CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DRONABINOL; EXATECAN; FLUOROURACIL; GEMCITABINE; IBUPROFEN; ICOSAPENTAENOIC ACID; IRINOTECAN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHYLPHENIDATE; METOCLOPRAMIDE; MITOMYCIN C; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PANCREAS ENZYME; RECOMBINANT ERYTHROPOIETIN; RUBITECAN; SEROTONIN UPTAKE INHIBITOR; THALIDOMIDE; UKRAIN; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT RESPIRATORY DISTRESS SYNDROME; ANALGESIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CACHEXIA; CANCER MORTALITY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER THERAPY; CONSTIPATION; DECOMPRESSION SURGERY; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DRUG MECHANISM; DYSPNEA; FATIGUE; FEVER; HEMOLYTIC UREMIC SYNDROME; HUMAN; METASTASIS; NAUSEA; NEUROLYSIS; OBSTRUCTIVE JAUNDICE; PANCREAS CANCER; PANCREAS INSUFFICIENCY; PANCREATICODUODENECTOMY; PATIENT CARE; PRIORITY JOURNAL; SMALL INTESTINE OBSTRUCTION; STOMACH OBSTRUCTION; UNITED STATES; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CACHEXIA; CHOLESTASIS; DEPRESSION; FATIGUE; HUMANS; PAIN; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; QUALITY OF LIFE;

EID: 0037280222     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-1-18     Document Type: Article

References (170)

1. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999;117:1464-1484.
2. Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
3. Evans DB, Abbruzzese JL Willett CG. Cancer of the pancreas. In: Cancer: Principles and Practice of Oncology, Sixth Edition: DeVita VT, Hellman S, Rosenberg SA, eds. Philadelphia, PA. Lippincott Williams and Wilkins, 2001:1126-1161.
4. Ryan DP, Grossbard ML. Pancreatic cancer: local success and distant failure. The Oncologist 1998;3:178-188.
5. Molinari M, Helton WS, Espat NJ. Palliative strategies for locally advanced unresectable and metastatic pancreatic cancer. Surg Clin North Am 2001;81:651-666.
6. Caraceni A, Weinstein SM. Classification of cancer pain syndromes. Oncology (Huntingt) 2001;15:1627-1642; discussion 1642-1643, 1646-1647.
7. Farrar JT, Portenoy RK. Neuropathic cancer pain: the role of adjuvant analgesics. Oncology (Huntingt) 2001;15:1435-1445; discussion 1445, 1450-1453.
8. Polati E, Finco G, Gottin L et al. Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer. Br J Surg 1998;85:199-201.
9. Kelsen DP, Portenoy RK, Thaler HT et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995;13:748-755.
10. Foley KM. Supportive care and quality of life: management of cancer pain. In: Cancer: Principles and Practice of Oncology, Sixth Edition: De Vita VT, Hellman S, Rosenberg SA, eds. Philadelphia, PA. Lippincott Williams and Wilkins, 2001:2977-3009.
11. Tham TC, Lichtenstein DR, Vandervoort J et al. Pancreatic duct stents for "obstructive type" pain in pancreatic malignancy. Am J Gastroenterol 2000;95:956-960.
12. Lillemoe KD, Cameron JL, Kaufman HS et al. Chemical splanchnicectomy in patients with unresectable pancreatic cancer: a prospective randomized trial. Ann Surg 1993;217:447-457.
13. Pietrabissa A, Vistoli F, Carobbi A et al. Thoracoscopic splanchnicectomy for pain relief in unresectable pancreatic cancer. Arch Surg 2000;135:332-335.
14. Delrio P, Izzo F, Cremona F et al. [Surgical options in the palliative treatment of pancreatic cancer.] Tumori 1999;85(suppl 1):S43-S46. Italian.
15. Choy YC, Puvenesvari S, Samad S. Chronic pain management-upper visceral malignancies coeliac plexus block with CT scanning - a case report. Med J Malaysia 1998;53:277-279.
16. Hol PK, Kvarstein G, Viken O et al. MRI-guided celiac plexus block. J Magn Reson Imaging 2000;12:562-564.
17. Gunaratnam NT, Sarma AV, Norton ID et al. A prospective study of EUS-guided celiac plexus neurolysis for pancreatic cancer pain. Gastrointest Endosc 2001;54:316-324.
18. Saenz A, Kuriansky J, Salvador L et al. Thoracoscopic splanchnicectomy for pain control in patients with unresectable carcinoma of the pancreas. Surg Endosc 2000;14:717-720.
19. Ceha HM, van Tienhoven G, Gouma DJ et al. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 2000;89:2222-2229.
20. Minsky BD, Hilaris B, Fuks Z. The role of radiation therapy in the control of pain from pancreatic carcinoma. J Pain Symptom Manage 1988;3:199-205.
21. Andre T, Balosso J, Louvet C et al. Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study. Int J Radiat Oncol Biol Phys 2000;46:903-911.
22. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
23. Rothenberg ML, Moore MJ, Cripps MC et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-353.
24. van den Bosch RP, van der Schelling GP, Klinkenbijl JH et al. Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas. Ann Surg 1994;219:18-24.
25. Sohn TA, Lillemoe KD, Cameron JL et al. Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 1999;188:658-669.
26. Di Fronzo LA, Cymerman J, Egrari S et al. Unresectable pancreatic carcinoma: correlating length of survival with choice of palliative bypass. Am Surg 1999;65:955-958.
27. Cooperman AM. Pancreatic cancer: the bigger picture. Surg Clin North Am 2001;81:557-574.
28. Terwee CB, Nieveen Van Dijkum EJ, Gouma DJ et al. Pooling of prognostic studies in cancer of the pancreatic head and periampullary region: the Triple-P study. Triple-P Study Group. Eur J Surg 2000;166:706-712.
29. Haringsma J, Huibregtse K. Biliary stenting with a prototype expandable Teflon endoprosthesis [Comment]. Endoscopy 1998;30:718-720.
30. Singh SM, Longmire Jr WP, Reber HA. Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg 1990;212:132-139.
31. Speer AG, Cotton PB, Russell RC et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987;2:57-62.
32. Buscail L, Pages P, Berthelemy P et al. Role of EUS in the management of pancreatic and ampullary carcinoma: a prospective study assessing resectability and prognosis. Gastrointest Endosc 1999;50:34-40.
33. Velanovich V, Wollner I, Ajlouni M. Staging laparoscopy promotes increased utilization of postoperative therapy for unresectable intra-abdominal malignancies. J Gastrointest Surg 2000;4:542-546.
34. Luque-de Leon E, Tsiotos GG, Balsiger B et al. Staging laparoscopy for pancreatic cancer should be used to select the best means of palliation and not only to maximize the resectability rate. J Gastrointest Surg 1999;3:111-118.
35. Espat NJ, Brennan MF, Conlon KC. Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass. J Am Coll Surg 1999;188:649-657.
36. DiFronzo LA, Egrari S, O'Connell TX. Choledochoduodenostomy for palliation in unresectable pancreatic cancer. Arch Surg 1998;133:820-825.
37. Walker PW. The anorexia/cachexia syndrome. Primary Care Cancer 2001;21:13-17.
38. Loprinzi C. Anorexia and cachexia. In: Cancer Management: A Multidisciplinary Approach. Sixth Edition, Publishers Research and Representation, Melville, NY; 2002:831-834.
39. Jatoi Jr A, Loprinzi CL. Current management of cancerassociated anorexia and weight loss. Oncology (Huntingt) 2001;15:497-502; discussion 508-510.
40. Ottery F. Supportive nutritional management of the patient with pancreatic cancer. Oncology (Huntingt) 1996;10(suppl):26-32.
41. Fearon KC, Barber MD, Falconer JS et al. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 1999;23:584-588.
42. Wigmore SJ, Todorov PT, Barber MD et al. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 2000;87:53-58.
43. Walsh D. Palliative management of the patient with advanced pancreatic cancer. Oncology (Huntingt) 1996;10(suppl):40-44.
44. Loprinzi CL, Ellison NM, Schaid DJ et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-1132.
45. Barber MD, McMillan DC, Preston T et al. Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement. Clin Sci (Lond) 2000;98:389-399.
46. Gogos CA, Ginopoulos P, Salsa B et al. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer 1998;82:395-402.
47. Wigmore SJ, Barber MD, Ross JA et al. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 2000;36:177-184.
48. Hussey HJ, Tisdale MJ. Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid. Br J Cancer 1999;80:1231-1235.
49. Wigmore SJ, Falconer JS, Plester CE et al. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 1995;72:185-188.
50. McMillan DC, Wigmore SJ, Fearon KC et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999;79:495-500.
51. McMillan DC, O'Gorman P, Fearon KC et al. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer 1997;76:788-790.
52. Ellison NM, Chevlen E, Still CD et al. Supportive care for patients with pancreatic adenocarcinoma: symptom control and nutrition. Hematol Oncol Clin North Am 2002;16:105-121.
53. Perez MM, Newcomer AD, Moertel CG et al. Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer 1983;52:346-352.
54. DiMagno EP, Malagelada JR, Go VL et al. Fate of orally ingested enzymes in pancreatic insufficiency. Comparison of two dosage schedules. N Engl J Med 1977;296:1318-1322.
55. Bruno MJ, Haverkort EB, Tijssen GP et al. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 1998;42:92-96.
56. Nevitt AW, Vida F, Kozarek RA et al. Expandable metallic prostheses for malignant obstruction of gastric outlet and proximal small bowel. Gastrointest Endosc 1998;47:271-276.
57. Huguier M, Mason NP. Treatment of cancer of the exocrine pancreas. Am J Surg 1999;177:257-265.
58. Casaccia M, Diviacco P, Molinello P et al. Laparoscopic palliation of unresectable pancreatic cancers: preliminary results. Eur J Surg 1999;165:556-559.
59. Yim HB, Jacobson BC, Saltzman JR et al. Clinical outcome of the use of enteral stents for palliation of patients with malignant upper GI obstruction. Gastrointest Endosc 2001;53:329-332.
60. Massie MJ, Holland JC, Depression and the cancer patient. J Clin Psychiatry 1990;51(suppl):12-19.
61. Cella D, Peterman A, Passik S et al. Progress toward guidelines for the management of fatigue. Oncology (Huntingt) 1998;12:369-377.
62. Von Hoff DD, Mahadevan D, Bears DJ. New developments in the treatment of patients with pancreatic cancer. Updates Clin Oncol 2001;4:1-15.
63. Anderson JS, Burris HA, Casper E et al. Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 1994;13:1600A.
64. Burris HA, Storniolo AM, Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997;33(suppl):S 18-S22.
65. Tempero M, Plunkett W, Ruiz Van Haperen V et al. Randomized phase II trial of dose intense gemcitabine by standard infusion vs fixed dose rate in metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1999;18:1048A.
66. Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol 1994;12:1527-1531.
67. Pavlakis N, Bell DR, Millward MJ et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80:286-291.
68. Fung MC, Storniolo AM, Nguyen B et al. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999;85:2023-2032.
69. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-3275.
70. Crown J, Casper ES, Botet J et al. Lack of efficacy of highdose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991;9:1682-1686.
71. DeCaprio JA, Mayer RJ, Gonin R et al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991;9:2128-2133.
72. Ardalan B, Singh G, Silberman H. A randomized phase I and II study of short-term infusion high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 1988;6:1053-1058.
73. Pazdur R, Ajani JJ, Abbruzzese JL et al. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 1992;70:2073-2076.
74. Scheithauer W, Pfeffel F, Kornek G et al. A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Cancer 1992;70:1864-1866.
75. Lutz MP, Koniger M, Muche R et al. A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer. Z Gastroenterol 1999;37:993-997.
76. Cartwright TH, Cohn A, Varkey JA et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160-164.
77. Wagener DJ, Verdonk HE, Dirix LY et al. Phase II trial of CPT11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995;6:129-132.
78. Sakata Y, Shimada Y, Yoshino M et al. [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer.] Gan To Kagaku Ryoho 1994;21:1039-1046. Japanese.
79. D'Adamo D, Hammond L, Donehower R et al. Final results of a phase II study of DX-8951f (exatecan mesylate, DX) in advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001;20:532a.
80. Rivkin S, Burris H, Gerstein H et al. A phase II study of rubitecan (RSF 2000, 9NC, 9-nitro-20(S)-camptothecin) in patients with refractory pancreatic cancer. Proc Am Soc Clin Oncol 2000;19:262a.
81. Okada S, Sakata Y, Matsuno S et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Br J Cancer 1999;80:438-443.
82. Rougier P, De Forni M, Adenis A et al. Phase II study of Taxotere® (RP56976, docetaxel) in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1994;13:200a.
83. Androulakis N, Kourousis C, Dimopoulos MA et al. Treatment of pancreatic cancer with docetaxel and granulocyte colonystimulating factor: a multicenter phase II study. J Clin Oncol 1999;17:1779-1785.
84. Rougier P, Adenis A, Ducreux M et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000;36:1016-1025.
85. Androulakis N, Stathopoulos G, Tsavaris N et al. First-line treatment with docetaxel and gemcitabine in patients with inoperable pancreatic cancer: a multicenter phase II study [abstract]. Eur J Cancer 1999;35:S142-S143.
86. Jacobs AD, Otero H, Picozzi V et al. Gemcitabine (G) and Taxotere® (T) in patients with unresectable pancreatic carcinoma. Proc Am Soc Clin Oncol 1999;18:1103A.
87. Whitehead RP, Jacobson J, Brown TD et al. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 1997;15:2414-2419.
88. Wils J, Bleiberg H, Blijham G et al. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1985;21:191-194.
89. Kornek G, Raderer M, Schenk T et al. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophagecolony stimulating factor in patients with advanced pancreatic adenocarcinoma. Cancer 1995;76:1356-1362.
90. Wils JA, Kok T, Wagener DJ et al. Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 1993;29A:203-204.
91. Rougier P, Ducreux M, Ould Kaci M et al. Randomized phase II study of oxaliplatin alone (OXA), 5-fluorouracil (5-FU) alone, and the two drugs combined (OXA-FU) in advanced or metastatic pancreatic adenocarcinoma (APC). Proc Am Soc Clin Oncol 2000;19:262a.
92. Moertel CG, Rubin J, O'Connell MJ et al. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 1986;4:1053-1057.
93. Rothman H, Cantrell Jr JE, Lokich J et al. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. Cancer 1991;68:264-268.
94. Rougier P, Ducreux M, Douillard JY et al. Efficacy of 5-FU + cisplatin (FUP) compared to bolus 5-FU (FU) in advanced pancreatic carcinoma (APC): a randomized trial from the French Anticancer Centers Digestive Group (FNLCCDG). Proc Am Soc Clin Oncol 1999;18:274a.
95. Rougier P, Zarba JJ, Ducreux M et al. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1993;4:333-336.
96. Andre T, Lotz JP, Bouleuc C et al. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol 1996;7:173-178.
97. Charles A, Heider A, Steffens F et al. 5-Fluorouracil/cisplatin in the treatment of advanced pancreatic cancer. Proc Am Soc Clin Oncol 1999;18:280a.
98. Philip PA, Zalupski M, Vaitkevicius VK et al. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer. Proc Am Soc Clin Oncol. 1999;18:274a.
99. Heinemann V, Wilke H, Possinger K et al. Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer. Final results of a phase II 1 study. Proc Am Soc Clin Oncol 1999;18:274a.
100. Heinemann V, Quietzsch D, Gieseler F et al. Gemcitabine plus cisplatin versus gemcitabine in advanced pancreatic cancer. Preliminary results of a phase III trial. Proc Am Soc Clin Oncol 2001;20:157a.
101. Louvet C, André T, Lledo G et al. Gemcitabine-oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): a GERCOR multicenter phase II study. Proc Am Soc Clin Oncol 2001;20:127a.
102. Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902-910.
103. Woynarowski JM, Napier C, Koester SK et al. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol 1997;54:1181-1193.
104. Herzig MC, Arnett B, MacDonald JR et al. Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). Biochem Pharmacol 1999;58:217-225.
105. Eckhardt SG, Baker SD, Britten CD et al. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol 2000;18:4086-4097.
106. Wang W, Waters SJ, MacDonald JR et al. Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells. Anticancer Res 2001;21:1789-1794.
107. Von Hoff DD, Cox JV, Tempero MA et al. Phase II trial of irofulven (MGI 114) in patients with advanced pancreatic cancer who have progressed on gemcitabine. Proc Am Soc Clin Oncol 2000;19:309a.
108. Ramadani M, Gansauge S, Muehling B et al. Ukrain (NSC-631570) is a strong mitotic inhibitor and induces apoptosis in pancreatic cancer cells. Pancreas 2001;23:456.
109. Zemskov VS, Procopchuk OL, Susak YM et al. Ukrain (NSC-631570) in the treatment of pancreas cancer. Drugs Exp Clin Res 2000;26:179-190.
110. Zemskov V, Prokopchuk O, Susak Y et al. Efficacy of ukrain in the treatment of pancreatic cancer. Langenbecks Arch Surg 2002;387:84-89.
111. Gansauge F, Ramadani M, Pressmar J et al. NSC-631570 (ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial. Langenbecks Arch Surg 2002;386:570-574.
112. Mallinson CN, Rake MO, Cocking JB et al. Chemotherapy in pancreatic cancer: result of a controlled, prospective, randomised, multicentre trial. Br Med J 1980;281:1589-1591.
113. Cullinan S, Moertel CG, Wieand HS et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990;65:2207-2212.
114. Smith FP, Hoth DF, Levin B et al. 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 1980;46:2014-2018.
115. Bitran JD, Desser RK, Kozloff MF et al. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin, and mitomycin C (FAM). Cancer Treat Rep 1979;63:2049-2051.
116. Bukowski RM, Abderhalden RT, Hewlett JS et al. Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas. Cancer Clin Trials 1980;3:321-324.
117. Cullinan SA, Moertel CG, Fleming TR et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-2067.
118. Di Costanzo F, Canaletti R, Sdrobolini A et al. Modulation of fluorouracil by methotrexate, leucovorin, and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC). Am J Clin Oncol 2000;23:314-318.
119. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
120. Raderer M, Kornek GV, Hejna MH et al. Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: a phase II study. Ann Oncol 1997;8:797-799.
121. Tsavaris N, Tentas K, Tzivras M et al. Combined epirubicin, 5-fluorouracil and folinic acid vs no treatment for patients with advanced pancreatic cancer: a prospective comparative study. J Chemother 1998;10:331-337.
122. Anchisi S, Delaloye B, Petite J et al. Gemcitabine and continuous infusional 5-fluorouracil is active and well tolerated in advanced or metastatic pancreatic cancer. Proc Am Soc Clin Oncol 2000;19:326a.
123. Pastorelli D, Pedralzzoli S, Sperti C et al. Phase II trial with gemcitabine + 5-fluorouracil in advanced pancreatic cancer. Proc Am Soc Clin Oncol 2000;19:284a.
124. Cascinu S, Silva RR, Barni S et al. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of the Digestive Tract Cancer (GISCAD). Br J Cancer 1999;80:1595-1598.
125. Louvet C, Hammel P, Andre T et al. Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5-FU, bolus and infusion, and gemcitabine (FOLFUGEM regimen). Proc Am Soc Clin Oncol 1999;18:275a.
126. Kreil A, Bauer J, Scheithauer W. [In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma.] Acta Med Austriaca 1999;26:93-100. German.
127. Hidalgo M, Castellano D, Paz-Ares L et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999;17:585-592.
128. Rocha Lima CM, Savarese D, Bruckner H et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002;20:1182-1191.
129. Stathopoulos G, Rigatos G, Dimopoulos M et al. Front-line treatment of pancreatic carcinoma with gemcitabine in combination with irinotecan: preliminary results of a multicenter phase II study. Proc Am Soc Clin Oncol 2000;19:319a.
130. Jacobs A, Otero H, Picozzi V et al. A phase I/II study of gemcitabine and docetaxel in patients with unresectable pancreatic cancer. Proc Am Soc Clin Oncol 2000;19:265a.
131. Cascinu S, Gasparini G, Catalano V et al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 1999;10:1377-1379.
132. Jacobs A, Otero H, Oicozzi V et al. Gemcitabine and Taxotere® in patients with unresectable pancreatic carcinoma. Proc Am Soc Clin Oncol 1999;18:288a.
133. Kakolyris S, Stathopoulos G, Tsavaris N et al. First-line treatment with docetaxel and gemcitabine in patients with advanced pancreatic cancer: a multicenter phase II study. Proc Am Soc Clin Oncol 1999;18:250a.
134. Garnier C, Rebischung C, Chirpaz E et al. Phase II study of a combination with leucovorin (LV), 5-FU bolus and infusion (FU), gemcitabine and oxaliplatin (FOLFU GEMOX regimen) in locally advanced (LA) and metastatic (M) pancreatic carcinoma (APC). Proc Am Soc Clin Oncol 2001;20:156a.
135. Reni M, Passoni P, Panucci MG et al. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001;19:2679-2686.
136. Kozuch P, Araneo M, Homel P et al. Biweekly sequential gemcitabine, 5-FU (5-fluorouracil), LV (leucovorin), and cisplatin (GFP): a highly active novel combination for metastatic adenocarcinoma of the exocrine pancreas (MPAC). Proc Am Soc Clin Oncol 2001;20:155a.
137. Kozuch P, Grossbard ML, Barzdins A et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. The Oncologist 2001;6:488-495.
138. El Kamar F, Bruckner HW, Jindal K et al. Irinotecan combined with gemcitabine, 5-FU (5-fluorouracil), LV (leucovorin), and cisplatin (G-FLIP) is an effective first-line regimen for metastatic adenocarcinoma of the exocrine pancreas (MPAC). Pancreas 2001;23:435.
139. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-6565.
140. Safran H, Ramanathan R, Schwartz J et al. Herceptin® and gemcitabine for metastatic pancreatic cancer that overexpress her-2/neu. Proc Am Soc Clin Oncol 2001;20:142a.
141. Abbruzzese J, Rosenberg A, Xiong Q et al. Phase II study of anti-epidermal growth factor receptor antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001;20:130a.
142. Barker AJ, Gibson KH, Grundy W et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-1914.
143. Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000;60(suppl 1):33-42.
144. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279.
145. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-1074.
146. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein famesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999;17:3631-3652.
147. Rowinsky EK. Clinical trials with therapeutics targeting Ras - Update 2001: appropriate expectations? Unfinished business. Molecular targets and cancer therapeutics. Proceedings of the AACR-NCI-EORTC International Conference 2001. Clin Cancer Res 2001;7(suppl 5):819.
148. Adjei AA, Erlichman C, Davis JN et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000;60:1871-1877.
149. Zujewski J, Horak ID, Bol CJ et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000;18:927-941.
150. Kim KB, Shin DM, Summey CC et al. Phase I study of farnesyl transferase inhibitor BMS-214662 in solid tumors. Proc Am Soc Clin Oncol 2001;20:79a.
151. Camacho LH, Soignet SL, Pezzuli S et al. Dose escalation study of oral farnesyl transferase inhibitor BMS-214662 in patients with solid tumors. Proc Am Soc Clin Oncol 2001;20:79a.
152. Lersch C, Van Cutsem E, Amado R et al. Randomized phase II study of SCH66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 2001;20:153a.
153. Cohen SJ, Ho L, Ranganathan S et al. Phase II and pharmacodynamic trial of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 2002;22:137a.
154. Macdonald JS, Chansky K, Whitehead R et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol 2002;22:138a.
155. Van Cutsem E, Karasek P, Oettle H et al. Phase III trial comparing gemcitabine + R115777 (Zarnestra®) versus gemcitabine + placebo in advanced pancreatic cancer. Proc Am Soc Clin Oncol 2002;22:130a.
156. Koshiba T, Hosotani R, Wada M et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998;82:642-650.
157. Bachem MG, Schmidt-Kotsas A, Fink M et al. Stimulating interactions between pancreatic stellate cells and tumor cells: implications on matrix turnover and cancer progression. Pancreas 2001;23:429.
158. Rowinsky EK, Humphrey R, Hammond LA et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000;18:178-186.
159. Hurwitz H, Humphrey J, Williams K et al. A phase I trial of BMS-275291: a novel non-hydrozamate, sheddase-sparing matrix metalloproteinase inhibitor with no dose-limiting arthritis. Proc Am Soc Clin Oncol 2001;20:98a.
160. Steward WP, Thomas AL. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs 2000;9:2913-2922.
161. Bramhall SR, Rosemurgy A, Brown PD et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001;19:3447-3455.
162. Carmichael J, Ledermann JA, Woll PJ et al. Phase IB study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer. Proc Am Soc Clin Oncol 1998;17:232a.
163. Laird AD, Vajkoczy P, Shawver LK et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152-4160.
164. Mendel DB, Laird AD, Smolich BD et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000;15:29-41.
165. Fong TA, Shawver LK, Sun L et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
166. Smith JP, Fantaskey AP, Liu G et al. Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol 1995;268:R135-R141.
167. Goetze JP, Nielsen FC, Burcharth F et al. Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 2000;88:2487-2494.
168. Gilliam AD, Henwood M, Watson SA et al. G17DT therapy may improve the survival of patients with advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 2001;20:134a.
169. Palmer KR, Kerr M, Knowles G et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81:882-885.
170. Narimanov M, Bazin I, Tryakin A et al. MMC based combinations in patients with advanced pancreatic cancer (APC). Ann Oncol 2000;11(suppl 4):68a.